C Ray Therapeutics Highlights Emerging Protein Scaffolds in Radioligand Therapy

According to a recent LinkedIn post from C Ray Therapeutics, the company is using its role as co-organizer of the International RDC Sub-Forum at XDC 2026 in Chengdu to spotlight emerging approaches in radioligand therapy design. The post highlights a planned presentation by Chris-Carol Bremer, Chief Development Officer at Navigo Proteins GmbH, on the development of innovative ligand-based radiopharmaceuticals.

The LinkedIn post describes a core technical challenge in radioligand therapy: matching ligand pharmacokinetics with the short half-lives of therapeutic isotopes such as Pb-212 and Ac-225. It suggests that traditional large-antibody approaches may create a “kinetic mismatch,” potentially leading to higher bone marrow exposure and suboptimal therapeutic indices.

As outlined in the post, the conference session will explore whether ultra-small protein scaffolds around 8.5 kDa can offer antibody-like binding affinity while enabling faster tissue penetration and clearance. The discussion is also set to cover site-specific conjugation strategies that could allow more controlled isotope-to-carrier ratios compared with conventional antibody systems.

The post indicates that C Ray Therapeutics aims to position itself at the intersection of European protein engineering and Asian radiopharma manufacturing through its involvement in XDC 2026. For investors, this focus may signal strategic alignment with next-generation radiopharmaceutical platforms, which could influence future partnership opportunities and technology access.

If alternative protein scaffolds gain traction as a new targeting standard, companies active in this space could benefit from differentiated intellectual property and potentially improved clinical profiles. While the post does not disclose specific pipeline assets, financing, or commercial timelines, C Ray Therapeutics’ visible role in convening technical dialogue may enhance its industry network and deal-making prospects in the radioligand therapy segment.